Your browser doesn't support javascript.
ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic.
Yahalom, Joachim; Dabaja, Bouthaina Shbib; Ricardi, Umberto; Ng, Andrea; Mikhaeel, N George; Vogelius, Ivan R; Illidge, Tim; Qi, Shunan; Wirth, Andrew; Specht, Lena.
  • Yahalom J; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Dabaja BS; MD Anderson Cancer Center, Houston, TX.
  • Ricardi U; Department of Oncology, University of Turin, Turin, Italy.
  • Ng A; Dana-Farber Cancer Institute, Boston, MA.
  • Mikhaeel NG; Guy's & St Thomas' Hospital, London, United Kingdom.
  • Vogelius IR; Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Illidge T; National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, The University of Manchester, Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom.
  • Qi S; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China; and.
  • Wirth A; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia.
  • Specht L; Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Blood ; 135(21): 1829-1832, 2020 05 21.
Article in English | MEDLINE | ID: covidwho-45899
ABSTRACT
The International Lymphoma Radiation Oncology Group (ILROG) guidelines for using radiation therapy (RT) in hematological malignancies are widely used in many countries. The emergency situation created by the COVID-19 pandemic may result in limitations of treatment resources. Furthermore, in recognition of the need to also reduce the exposure of patients and staff to potential infection with COVID-19, the ILROG task force has made recommendations for alternative radiation treatment schemes. The emphasis is on maintaining clinical efficacy and safety by increasing the dose per fraction while reducing the number of daily treatments. The guidance is informed by adhering to acceptable radiobiological parameters and clinical tolerability. The options for delaying or omitting RT in some hematological categories are also discussed.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Hematologic Neoplasms / Lymphoma Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Blood Year: 2020 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Hematologic Neoplasms / Lymphoma Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Blood Year: 2020 Document Type: Article